BAIVF (Benevolent AI) FCF Margin % : -587.11% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Benevolent AI's Free Cash Flow for the six months ended in Dec. 2023 was $-15.12 Mil. Benevolent AI's Revenue for the six months ended in Dec. 2023 was $2.58 Mil. Therefore, Benevolent AI's FCF Margin % for the quarter that ended in Dec. 2023 was -587.11%.

As of today, Benevolent AI's current FCF Yield % is -70.04%.

The historical rank and industry rank for Benevolent AI's FCF Margin % or its related term are showing as below:

BAIVF' s FCF Margin % Range Over the Past 10 Years
Min: -1077.38 Med: -741.44 Max: -526.64
Current: -794.13

During the past 6 years, the highest FCF Margin % of Benevolent AI was -526.64%. The lowest was -1077.38%. And the median was -741.44%.

BAIVF's FCF Margin % is ranked worse than
72.35% of 1049 companies
in the Biotechnology industry
Industry Median: -143.87 vs BAIVF: -794.13

Benevolent AI FCF Margin % Historical Data

The historical data trend for Benevolent AI's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI FCF Margin % Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-639.31

-526.60

-1,077.43

-739.31

-794.27

Benevolent AI Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial				-1,024.86	-882.85	-617.75	-873.83	-587.11

Competitive Comparison of Benevolent AI's FCF Margin %

For the Biotechnology subindustry, Benevolent AI's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Benevolent AI's FCF Margin % falls into.

Benevolent AI FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Benevolent AI's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-73.708	/	9.28
	=	-794.27 %

Benevolent AI's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-15.118	/	2.575
	=	-587.11 %

Benevolent AI FCF Margin % Related Terms

Thank you for viewing the detailed overview of Benevolent AI's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.